A national clinical trial of 96 HIV-positive children and adolescents showed that 53% of them achieved an undetectable amount of HIV in their blood after 24 weeks of treatment with raltegravir, which was recently approved by the FDA for use in children. The drug had no significant toxicities or interactions with other HIV drugs, the lead researcher said in a statement.

Related Summaries